Covered recipient · General Payments record
CHRISTOPHER S CONNELLY
Allopathic & Osteopathic Physicians Psychiatry & Neurology Clinical Neurophysiology
General Payments · PY2020–2023
$374.43
- Reported across 20 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $308.10 | 16 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $54.31 | 2 |
| ABBVIE INC. | $46.74 | 2 |
| Celgene Corporation | $43.18 | 2 |
| TG THERAPEUTICS, INC. | $37.68 | 2 |
| PFIZER INC. | $34.15 | 2 |
| Xeris Pharmaceuticals, Inc. | $27.73 | 2 |
| Genentech USA, Inc. | $17.92 | 1 |
| Lilly USA, LLC | $16.14 | 1 |
| Teva Pharmaceuticals USA, Inc. | $15.97 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $14.28 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $18.42 | 02/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996502307 | CMS |
| AbbVie Inc. | $28.32 | 08/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 996502311 | CMS |
| Biogen, Inc. | $26.90 | 07/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1012243123 | CMS |
| Biogen, Inc. | $27.41 | 09/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1012232389 | CMS |
| Celgene Corporation | $20.21 | 03/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015654285 | CMS |
| Celgene Corporation | $22.97 | 08/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1015654439 | CMS |
| Genentech USA, Inc. | $17.92 | 06/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1040330613 | CMS |
| Lilly USA, LLC | $16.14 | 03/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1031328977 | CMS |
| Novartis Pharmaceuticals Corporation | $14.28 | 08/30/2023 | Food and Beverage | Undisputed | 01/23/2026 | 991857213 | CMS |
| PFIZER INC. | $17.29 | 02/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049532197 | CMS |
| PFIZER INC. | $16.86 | 07/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050555817 | CMS |
| Teva Pharmaceuticals USA, Inc. | $15.97 | 09/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1056993023 | CMS |
| TG Therapeutics, Inc. | $22.21 | 09/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1051500061 | CMS |
| TG Therapeutics, Inc. | $15.47 | 11/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1051500205 | CMS |
| Xeris Pharmaceuticals, Inc. | $13.17 | 04/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1056450849 | CMS |
| Xeris Pharmaceuticals, Inc. | $14.56 | 05/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1056450853 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2022, 2023
- Source files
- Dataset page · Bulk file · PY2020 , PY2022 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.